SCHEMBL4828753

SCHEMBL4828753

NC(=O)Cc1ccc(-c2ccnc(Nc3cccc(N4CCN(C(=O)Cc5ccccc5)CC4)c3)n2)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 4/20 0.55
HDAC1 Q13547 1/20 0.51
HDAC6 Q9UBN7 1/20 0.51
JAK3 P52333 1/20 0.51
GSK3B P49841 4/20 0.50
MAPK8 P45983 3/20 0.50
PIK3CG P48736 2/20 0.50
CAMKK2 Q96RR4 2/20 0.50
CDK2 P24941 4/20 0.49
LCK P06239 3/20 0.49
CSF1R P07333 3/20 0.49
FGFR1 P11362 3/20 0.49
KDR P35968 3/20 0.49
TAOK1 Q7L7X3 3/20 0.49
MAP4K5 Q9Y4K4 3/20 0.49
FLT3 P36888 3/20 0.49
PRKD3 O94806 2/20 0.49
SRC P12931 2/20 0.49
SYK P43405 2/20 0.49
GSK3A P49840 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4603072 0.91 JAK2 (0.54) JAK2HDAC1HDAC6JAK3GSK3B
SCHEMBL4382278 0.88 JAK2 (0.72) JAK2HDAC1HDAC6JAK3CDK2
SCHEMBL4762218 0.88 JAK2 (0.70) JAK2HDAC1HDAC6JAK3GSK3B
SCHEMBL4603101 0.83 JAK2 (0.55) JAK2HDAC1HDAC6JAK3GSK3B
SCHEMBL4384202 0.81 JAK2 (0.69) JAK2HDAC1HDAC6JAK3CDK2
SCHEMBL4602091 0.80 GSK3B (0.57) JAK2HDAC1HDAC6JAK3GSK3B
SCHEMBL4600894 0.78 CCNT1 (0.51) JAK2JAK3GSK3BMAPK8PIK3CG
SCHEMBL4375224 0.78 JAK2 (0.77) JAK2HDAC1HDAC6JAK3CDK2
SCHEMBL4558034 0.77 JAK2 (0.58) JAK2HDAC1HDAC6JAK3GSK3B
SCHEMBL3753315 0.77 MAPK8 (0.62) JAK2JAK3GSK3BMAPK8PIK3CG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1979329-A2 4-ARYL-2-AMINO-PYRIMIDINES OR 4-ARYL-2-AMINOALKYL-PYRIMIDINES AS JAK-2 MODULATORS AND METHODS OF USE Exelixis, Inc. (US) 2008-10-15 EP disclosed
WO-2007089768-A2 4-ARYL-2-AMINO-PYRIMIDINES OR 4-ARYL-2-AMINOALKYL-PYRIMIDINES AS JAK-2 MODULATORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM EXELIXIS, INC. (US) 2007-08-09 WO disclosed